Elevated IL-17A level is associated with poor overall survival following immune checkpoint inhibitors combined with targeted therapy in hepatocellular carcinoma with hyperbilirubinemia

BackgroundCombination therapy with programmed death-1 (PD-1) inhibitors and targeted therapy is a first-line treatment for advanced hepatocellular carcinoma (HCC). Patients with hyperbilirubinemia (total bilirubin > upper limit of normal) are often excluded from such regimens. This study aimed to...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Jianing Wang, Shida Pan, Chuyue Xiong, Jiahe Tian, Yilin Wang, Yingying Yu, Siyu Wang, Yingjuan Shen, Luo Yang, Xiaomeng Liu, Junqing Luan, Mengdie Jia, Xuanxuan Duan, Fusheng Wang, Fanping Meng
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2026-04-01
Serie:	Frontiers in Immunology
Soggetti:	hepatocellular carcinoma hyperbilirubinemia prognosis proteomics survival
Accesso online:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1791538/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!